Basel

(redirected from Basilea)
Also found in: Dictionary, Thesaurus, Encyclopedia.

Basel

A town in Switzerland. It has been known for centuries as a meeting place where a number of international agreements have been formed. See also: Basel I, Basel II.

References in periodicals archive ?

Basilea's oncology drug candidate BAL101553 (the prodrug of BAL27862)4 is being developed as a potential therapy for diverse cancers.

Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 in brain cancer

As part of the agreement, Basilea will apply Forge's proprietary BLACKSMITH platform to develop potent and selective inhibitors against two historically difficult-to-drug, unexploited antibiotic targets.

Forge & Basilea partner to discover and develop novel antibiotics

Carta a Thomas Ebendorfer (1441), sobre el traslado del concilio a Ferrara, la responsabilidad de los presidentes de Basilea y el poder real del papa; 6.

Nicolas DE CUES: Unite et reforme. Dix opuscules ecclesiologiques

This report provides comprehensive information on the current therapeutic developmental pipeline of Basilea Pharmaceutica AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Basilea Pharmaceutica AG - Product Pipeline Review - 2015 - New Study Released

The deal will see Astellas, headquartered in Japan, and Basilea, headquartered in Switzerland, amend their existing licensing agreement, signed in 2010, to allow Astellas to secure exclusive commercialisation rights to Isavuconazole in the US and Canada.

Wragge & Co team advises on medical deal

(http://www.dailymotion.com/video/xzj3ht_chelsea-2-1-basilea-gol-de-moses-uefa-europa-league_sport) Chelsea 2-1 Basilea (Gol de Moses) UEFA EUROPA...

VIDEO Chelsea 3-1 FC Basel Highlights: Blues Advance With Second Half Flurry

The company reported a solid cash position, including short-term investments, of CHF 149 million as of June 30, 2012, which was further strengthened by an additional CHF 224 million following the recently announced completion of the transaction with Stiefel, a GSK company, related to Basilea's hand eczema drug Toctino (alitretinoin).